Bittl A, Nap M, Jäger W, Lathan B, Lang N
Department of Obstetrics and Gynecology, University of Erlangen, FRG.
Tumour Biol. 1993;14(3):155-66. doi: 10.1159/000217831.
In this study, the reactivity of three different monoclonal antibodies (MAbs) against the multiple-drug resistance (MDR)-related P-glycoprotein (P-170) were compared with each other using a collection of frozen and paraffin-embedded tumors, normal tissues and metastatic cells of malignant pleural and peritoneal effusions. The MAbs JSB-1, C 219 and 265/F4 were used in an indirect immunoperoxidase technique on frozen material. In addition, MAb C 219 was used on formalin-fixed, paraffin-embedded material from the same tumors, of which frozen sections were studied, and in a retrospective study C 219 was tested on paraffin blocks of the primary tumors that were responsible for the malignant effusions. The results show different staining patterns for all three MAbs to some extent. Results in frozen and paraffin sections obtained with MAb C 219 were comparable. MAb C 219 performs well both in frozen and formalin-fixed, paraffin-embedded material, making it a useful candidate for application in routine laboratory analysis. The retrospective analysis did not show consistency of P-170 expression in the same patients. This leads to the hypothesis that the actual status of P-170 expression in recurrent disease should be obtained before continuing or modifying chemotherapy. Clinical studies aimed at the correlation of immunohistochemistry with therapy response have to evaluate the relevance of P-170 expression in drug resistance of primary and metastatic tumors.
在本研究中,使用一组冷冻及石蜡包埋的肿瘤、正常组织以及恶性胸腔和腹腔积液的转移细胞,比较了三种不同的针对多药耐药(MDR)相关P-糖蛋白(P-170)的单克隆抗体(MAb)之间的反应性。MAb JSB-1、C 219和265/F4用于对冷冻材料进行间接免疫过氧化物酶技术检测。此外,MAb C 219用于对来自相同肿瘤的福尔马林固定、石蜡包埋材料进行检测,其中对冷冻切片进行了研究,并且在一项回顾性研究中,对导致恶性积液的原发性肿瘤的石蜡块进行了C 219检测。结果在一定程度上显示了所有三种MAb的不同染色模式。用MAb C 219获得的冷冻切片和石蜡切片结果具有可比性。MAb C 219在冷冻材料以及福尔马林固定、石蜡包埋材料中均表现良好,使其成为常规实验室分析应用中的一个有用候选物。回顾性分析未显示同一患者中P-170表达的一致性。这导致这样一种假设,即在继续或修改化疗之前,应了解复发性疾病中P-170表达的实际状态。旨在研究免疫组化与治疗反应相关性的临床研究必须评估P-170表达在原发性和转移性肿瘤耐药性中的相关性。